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Abstract
Background: Although substantiated by little evidence, concerns about zidovudine-related anaemia in pregnancy
have influenced antiretroviral (ARV) regimen choice for preventing mother-to-child transmission of HIV-1, especially
in settings where anaemia is common.
Methods: Eligible HIV-infected pregnant women in Burkina Faso, Kenya and South Africa were followed from 28 weeks
of pregnancy until 12–24 months after delivery (n = 1070). Women with a CD4 count of 200-500cells/mm3 and
gestational age 28–36 weeks were randomly assigned to zidovudine-containing triple-ARV prophylaxis continued
during breastfeeding up to 6-months, or to zidovudine during pregnancy plus single-dose nevirapine (sd-NVP) at labour.
Additionally, two cohorts were established, women with CD4 counts: <200 cells/mm3 initiated antiretroviral therapy,
and >500 cells/mm3 received zidovudine during pregnancy plus sd-NVP at labour. Mild (haemoglobin 8.0-10.9 g/dl) and
severe anaemia (haemoglobin < 8.0 g/dl) occurrence were assessed across study arms, using Kaplan-Meier and
multivariable Cox proportional hazards models.
Results: At enrolment (corresponded to amedian 32 weeks gestation), median haemoglobin was 10.3 g/dl (IQR = 9.2-11.1).
Severe anaemia occurred subsequently in 194 (18.1%) women, mostly in those with low baseline haemoglobin, lowest
socio-economic category, advanced HIV disease, prolonged breastfeeding (≥6months) and shorter ARV exposure. Severe an-
aemia incidence was similar in the randomized arms (equivalence P-value = 0.32). After 1–2months of ARV’s, severe
anaemia was significantly reduced in all groups, though remained highest in the low CD4 cohort.
Conclusions: Severe anaemia occurs at a similar rate in women receiving longer triple zidovudine-containing regimens or
shorter prophylaxis. Pregnant womenwith pre-existing anaemia and advanced HIV disease require closemonitoring.
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Background
Anaemia during pregnancy and lactation is common, af-
fecting ~40% of women globally [1,2]. Highest levels of an-
aemia in pregnancy occur in sub-Saharan Africa (SSA),
where an estimated 57% (~17 million) of all pregnant
women are anaemic (haemoglobin [Hb] < 11 g/dl) [3-6].
There is, however, marked variation in anaemia prevalence
among pregnant women across the continent, ranging from
41-83%. Anaemia levels are highest in malaria-endemic
areas [7], especially among the estimated one million preg-
nant women each year who are co-infected with malaria
and HIV [7,8]. HIV infection itself, as with other chronic
conditions, can cause anaemia [9]. A study among women
attending antenatal clinics in Kenya, found as many as two-
thirds of HIV-infected women were anaemic [10].
In addition to malaria and HIV, other factors account for
high levels of anaemia in Africa, such as under-nutrition
and iron deficiency, intestinal helminth infestation and
higher pregnancy rates [11]. Anaemia in pregnancy in-
creases risk of maternal mortality [12]. For each 1 g/dL
decrease in mean Hb in late pregnancy, maternal mortality
risk rises 20% (95% CI = 9-30%) [13]. Pregnant women with
anaemia require faster and more vigorous intervention
during pregnancy, delivery or postpartum should excessive
bleeding occur [14-16].
The antiretroviral (ARV) zidovudine (ZDV) affects bone
marrow function and can cause or exacerbate pre-existing
anaemia, in addition to its classical manifestation of mac-
rocytosis [17-20]. Concerns are heightened with use of this
drug in pregnant women in SSA, given high anaemia
levels and the limited capacity of health systems to re-
spond to its consequences in pregnancy.
Previous randomised trials have examined the haemato-
logical safety of ZDV prophylaxis for preventing mother-
to-child transmission (PMTCT). In these studies, ZDV was
taken only during pregnancy and labour for up to 12 weeks.
A randomised trial in Thailand, which compared women
taking ZDV from 36 weeks of pregnancy with those on pla-
cebo, found similar haematocrita at delivery (32% vs 33%).
Thirteen women receiving ZDV had severe postpartum an-
aemia (haematocrit < 25%), compared with 10 controls
[21]. No major differences were seen in a subsequent study
in Thailand [22]. In Cote d’Ivoire, with a similar PMTCT
regimen, no differences in Hb concentrations were noted
in women receiving ZDV compared with placebo [23,24].
A recent PMTCT trial in Malawi also did not find in-
creased anaemia when comparing a longer (28 week) and
shorter (1 week) ARV regimen [25], while by contrast
other cohort studies in Malawi and Mozambique found a
higher risk of anaemia in women taking a ZDV-containing
regimen compared with a stavudine-based triple ARV regi-
men [26]. Further, more definitive, evidence of effects of
current ARV regimens could inform policy and care for
HIV-infected pregnant women.
This study describes haematological changes among
women receiving ZDV-containing ARV regimens of
varying duration in Burkina Faso, Kenya and South
Africa. We assessed whether severe anaemia occurred
more commonly among women randomized to longer
ZDV-containing triple ARV prophylaxis in pregnancy
and continued during breastfeeding, compared to a
shorter regimen of ZDV in pregnancy and 1 week post-
partum only. We also identified sub-groups at risk for
severe anaemia.
Methods
Data from the Kesho Bora trial in Burkina Faso, Kenya
and South Africa were used. Detailed objectives, trial
methods and primary endpoint analyses are presented
elsewhere [27-30]. Pregnant women were enrolled from
five sites in Burkina Faso, Kenya and South Africa (re-
cruited at antenatal clinics) at 28–36 weeks gestation (or
earlier depending on HIV disease stage and time of entry
into study) and screened for eligibility after signing in-
formed consent. To be eligible, HIV-infected women
had to reside and plan to continue living in the study
area until two years post-delivery, have no contrain-
dication to receive ARVs, and no evidence of clinically
significant conditions (obstetric, cardiac, respiratory in-
cluding active tuberculosis, hepatic, gastrointestinal,
endocrine, renal, hematologic, psychiatric, neurologic, or
allergic) which may interfere with study interventions.
Fifteen women with severe anaemia (Hb < 7.0 g/dL) at
screening and who did not respond to medical manage-
ment were excluded from study participation. Eligible
women signed informed consent for study participation.
Relevant ethical approval for study procedures were
obtained [27].
HIV-infected pregnant women with WHO clinical
stage 4 or a CD4 cell count below 200 cells/mm3 were
enrolled in a prospective cohort (Cohort 1) and offered
long-term ARV treatment (ZDV, lamivudine [3TC] and
nevirapine [NVP]) beginning as early as possible in
pregnancy and continued thereafter. Women with a
CD4 >500 cells/mm3 were enrolled in a prospective co-
hort (Cohort 2) and offered a short-course regimen as
per WHO recommendations [2,31]: 300 mg ZDV taken
twice daily starting from 34 to 36 weeks of pregnancy
until the onset of labour, plus one 600 mg dose of ZDV
and 200 mg single dose (sd) of NVP at the onset of
labour. These prospective cohorts were not initiated in
South Africa. Women with intermediate immune status
(CD4 count 200–500 cells/mm3) were randomised to
receive an ARV prophylaxis regimen initiated between
28–36 weeks gestation, of either triple ARV prophylaxis
(ZDV [300 mg], 3TC [150 mg], Lopinavir/ritonavir
[LPV/r 400 mg/100 mg]) continued through delivery
and during breastfeeding up to 6 months postpartum
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(RCT arm A); or the same short-course prophylaxis regi-
men used in Cohort 2 (RCT arm B) based on available
WHO guidelines at the time from 2004 [31]. All infants
received sd-NVP [2 mg per kg body weight] within 72 hours
of birth. About midway through the trial (December 2006),
following an update in WHO recommendations [2],
women assigned the short-ARV regimen were also given
seven days of ZDV/3TC after delivery and all infants re-
ceived seven days of ZDV [4 mg per kg body weight] from
birth, to reduce occurrence of ARV drug resistance.
Women visited antenatal clinic every two weeks from
enrolment until delivery, following which mothers and
their babies attended clinic at two, four, six, and eight
weeks after delivery and then monthly until one year,
and every three months thereafter until 24 months [27].
Due to fluctuations in available resources, the study
protocol was altered in May 2006, restricting the follow-
up duration to 12 months post-delivery, but then ex-
tended to 18 months from January 2008 onwards [27].
Using face-to-face structured interviews, socio-demo-
graphic data were collected at enrolment and information
on variables such as infant feeding pattern were gathered
at each scheduled visit. Blood samples were taken and a
full blood count performed at: enrolment, 1 and 3 weeks
after initiating the ARV regimen; delivery; weeks 2 and 6
postpartum, and at months 3, 6, 9, 12 and 18 after deliv-
ery. Hb testing was also done at unscheduled visits, where
clinically indicated. This analysis utilized Hb measures
from both scheduled and unscheduled visits.
Participants received a basic care package during preg-
nancy, including iron and folate (1 tablet of 60 mg iron
plus 400 μg folate once daily for anaemia prevention, or
twice daily for anaemia treatment), multivitamins once
daily, presumptive treatment for malaria in endemic
areas (once during third trimester), and anti-helminthics
as recommended locally [27].
Individual ARV drugs causing toxicity were discontin-
ued without necessarily discontinuing the whole regimen.
If toxicity resolved, the drug could be restarted within
14 days. Full details of ARV options if permanent discon-
tinuation was necessary are described elsewhere [27].
Data analysis
Data were analysed using Stata 12.1 [32] and R [33].
Differences in Hb levels and occurrence of anaemia at
enrolment and subsequent follow-up visits were compared
among the cohort and trial arms using a Student’s t/
Analysis of variance (ANOVA) test and Chi-square test
respectively. We also used these tests to compare Hb and
related parameters such as mean cell volume [MCV],
mean cell Hb [MCH], haematocrit [HCT] and CD4 cell
count at follow-up time points. An MCV above 100 fl was
defined as macrocytosis [34]. For each woman, we also
calculated the change in Hb at each follow-up point,
compared to her enrolment Hb. The median of these
values was computed (plus 95% confidence intervals) at
each scheduled follow-up point, and compared between
the cohorts and RCT arms (Figure 1).
The primary outcome is occurrence of severe anaemia
(defined as Hb < 8.0 g/dL) from study enrolment until
18 months follow-up, comparing the two RCT arms
(and the two cohorts). Kaplan-Meier product-limit esti-
mates were computed and log rank tests used to com-
pare incidence of severe anaemia by cohort and RCT
arm (Figure 2) and stratified by Hb level at enrolment
for RCT arms only (Figure 3).
The aetiology of anaemia in pregnancy, especially in
SSA, is complex and multi-factorial [35,36]. The follow-
ing explanatory variables were considered when asses-
sing the primary endpoint in bivariate and multivariable
analysis: country, socio-demographic characteristics (age
and education) and socio-economic status (SES) score at
enrolment, body mass index [BMI], parity [first preg-
nancy versus 1 or more previous pregnancies], ever
breastfed and prolonged duration of breastfeeding [none,
<6 months, ≥6 months], advanced WHO HIV disease
stage [classified as 3 or 4], and time-varying duration of
ZDV use. SES was calculated using a weighted score
from a principal component factor analysis based on
eight household assets and divided into quintiles within
each country.
The risk factor analyses were split into individual co-
horts and RCT trial arms combined given the differences
in the observational cohorts and absence of cohorts in
South Africa. Women with severe anaemia were not
considered at risk of another diagnosis of severe anaemia
unless their Hb level returned to a value ≥8 g/dl. Vari-
ables significantly associated with severe anaemia at the
10% level were selected for inclusion into the various
multivariable Cox non-parametric proportional hazards
regression models, using an ordered multiple-failure
stratified robust approach [37,38]. In addition to testing
for difference, testing for equivalence of the two trial
arms was done using the Westlake approach [39] with a
dissimilarity significance cut-off of 5%. Model fit and
diagnostics were also run to ensure no violation of the
proportional hazards assumption occurred.
Results
Between January 2005 and August 2008, 1072 pregnant
women enrolled, 345 in Burkina Faso, 441 in Kenya and
284 in South Africa. Two women were excluded: one
from Cohort 1 (abortion) and another from Cohort 2
(maternal death prior to delivery). Of the remaining, 118
initiated long-term antiretroviral treatment (Cohort 1;
118/1070; 11.0%) and 128 women received ZDV plus
sdNVP in Cohort 2 (128/1070; 12.0%). The rest were
randomized to triple ARV prophylaxis (RCT arm A,
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N= 412) or ZDV plus sdNVP (RCT arm B, N = 412).
Eight women stopped or changed treatment due to
anaemia (5 in Cohort 1, 3 in RCT arm A).
Population description
Median age of participants ranged between 26 and 28 years
across observation cohorts and trial arms (Table 1) and
was similar across countries. Participants in South Africa
had a higher SES than in Burkina Faso and Kenya
(P-value < 0.001) with 57.4% (N = 284) of South Africans
in the wealthiest SES category compared to only 6.4%
(N = 346) in Burkina Faso and 6.1% (N = 440) in Kenya.
SES was thus lower in the cohorts than RCT arms, given
the absence of South African cohorts. Previous pregnancy
was more common in Cohort 1 than 2, or the trial arms.
Women in Cohort 1 had more advanced HIV clinical
disease, while the majority in Cohort 2 was asymptom-
atic (78%). CD4 cell count at enrolment was similar be-
tween the two RCT arms, but was higher in Arm A than
B at childbirth and more than 150 cells higher at
6 months postpartum. At enrolment, the lowest mean
body mass index (BMI) and highest proportion under-
weight (BMI < 18.5), was observed in Cohort 1. The
RCT arms were balanced, with no differences detected
in haematological or other measures at baseline.
About 75% of women in each trial arm and Cohort 2
initiated breastfeeding, compared to only 62% of those
in Cohort 1 (Table 2). Duration of breastfeeding was,
however, similar among those who did initiate breast-
feeding in each group. As per study design, median dur-
ation of ARV use was 171.5 days in RCT arm A,
compared with 65.5 days in RCT arm B (P-value < 0.001,
Table 2), while women in Cohort 1 took ARV’s for a me-
dian 811.5 days. The median duration on ARV prior to
childbirth in all arms was 5.0 weeks (Interquartile range
[IQR] = 3.0-7.4), ranging from 5.4 weeks (IQR = 3.7-7.7)
in Cohort 1, 4.6 weeks (IQR = 3.6-6.3) in Cohort 2, and
5.0 weeks in the RCT arms (IQR = 2.6-7.3 and 3.0-8.1 in
RCT arm A and B respectively).
Haematological measures
At enrolment, mean Hb was 10.3 g/dL (standard deviation
[SD] = 1.7 g/dL) and 69.9% had anaemia (<11.0 g/dL),
highest in Burkina Faso (79.3%) followed by Kenya (70.3%)
and South Africa (57.8%; P-value < 0.001). Mean Hb in
the lowest SES quintile was 10.1 g/dL (SD = 1.9) at enrol-
ment compared to 10.7 (SD = 1.6) in the wealthiest quintile
(P-value < 0.001). Though mean Hb in Cohort 1 (10.1)
was a full 1 g/dL lower than in Cohort 2 at enrolment
(11.2, P-value < 0.001), by 6 months postpartum, no
Cohort 1: ART (CD4 cell count <200) Cohort 2: ZDV plus sdNVP (CD4 cell count >500)
Time in months (since enrolment) with 0 representing delivery
Time in months (since enrolment) with 0 representing delivery
Figure 1 Median change (with 95% confidence intervals) in Hb level in the months before and after delivery (t = 0) by
intervention arm.
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differences were detected between mean Hb in these two
groups and the average Hb was similar at month 12.
In Cohort 1, the proportion of women with macrocy-
tosis increased to nearly two-thirds at months 6 and 12
(Table 2). At 6 months postpartum, mean MCV levels
were significantly higher in RCT arm A than arm B (91
vs 85 fl), but differences were not detected between trial
arms at other time points. However, the proportion with
macrocytosis decreases significantly within 3 months
after treatment cessation in both RCT arms i.e. by
month 3 post childbirth for RCT arm B and by month 9
post childbirth for RCT arm A, as per design.
Across all study groups, a rapid and substantial increase
in Hb was observed after initiation of ARVs especially fol-
lowing childbirth (P-value < 0.001 in each study group
using repeated measures ANOVA assessing mean change
at multiple time points). Increases in Hb in each of the
time intervals reached a plateau of 1.5-2.0 g/dL median
rise in Hb compared to enrolment levels (Figure 1). In
Cohort 2, however, we observed a subsequent decrease in
Hb following ARV cessation, though this group did have a
higher median enrolment Hb compared to the other arms
and attained higher median gains within the first 3 months
of follow-up compared to the RCT arms (Figure 1). The
median rise (and plateau) in Hb in the two trial arms was
very similar with minor non-statistically significant differ-
ences (Table 2). Both arms appeared to maintain these
levels through the follow-up period (Figure 1).
The highest period prevalence of severe anaemia in
the period between enrolment and delivery was observed
A
B
Figure 2 Kaplan-Meier failure curve showing anaemia failure (Hb <8.0 g/dL) by intervention arm, with onset of risk at enrolment
(Figure 2A) and at delivery (Figure 2B), censored at 18 months follow-up.
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in Kenya (8.4%, P-value < 0.001). Kaplan-Meier failure
curves for severe anaemia by intervention arm suggests
that most failures occurred within the first two months
after initiation of ARV drugs (Figure 2), which corre-
sponds largely with the period between enrolment and
childbirth. We observed a strong reduction in severe an-
aemia incidence with increasing duration of receiving
ARV (Figure 4) – further confirmed in the multivariate
analysis below. More than one month on ARV’s was as-
sociated with a marked decrease in severe anaemia risk
when compared to under one month on ARV’s (i.e. same
individuals either side of this duration cut-off ). Longer
ARV duration (two or more months) further signifi-
cantly reduced anaemia incidence. We observed 64 cases
of anaemia among breastfeeding women at a rate of 54
per 1000 person-years (95% CI = 42-69) compared to 24
cases or 52 per 1000 (95% CI = 35-77) among women
who did not breastfeed at all (log rank P-value = 0.830).
A log rank test comparing all four groups indicated a
highly significant difference in failure functions (Figure 2),
irrespective of using date of enrolment or delivery as com-
mencement of risk. The highest incidence of severe an-
aemia was observed in Cohort 1 and lowest in Cohort 2.
The cumulative incidence proportion of severe anaemia at
18 months postpartum was highest in Cohort 1 (0.34)
followed by RCT arm B (0.21), RCT arm A (0.18) and low-
est in Cohort 2 (0.11; Table 2). No difference was detected
in the failure function of the two RCT arms (log-rank
P-value = 0.344). Based on equivalence testing, dissimilar-
ity could also not be rejected i.e. RCT arms were equiva-
lent (P-value = 0.323). Kaplan-Meier analysis of severe
anaemia failure in the RCT arms, stratified by enrolment
Hb level, showed a higher risk of severe anaemia failure in
the group that had mild anaemia at enrolment (Hb 8.0-
11.0 g/dL), compared to those with no anaemia at enrol-
ment (Hb >11.0 g/dL) (log rank P-value < 0.001; Figure 3).
No difference (log rank P-value = 0.587) was detected in
severe anaemia failure in the RCT arms comparing those
who had mild anaemia at enrolment. However, despite
small numbers, higher failure (P-value = 0.026) was ob-
served in RCT arm B than in RCT arm A in women with
enrolment Hb > 11.0 g/dL (Figure 3), though this does not
adjust for explanatory or confounding factors.
In multivariable analysis of the observational cohorts,
increasing duration on ARV was found to be highly pro-
tective in cohort 1 (hazard ratio (HR) = 0.04; P-value =
0.002) while the lowest SES group had a 4.1 higher
hazard ratio (HR) of severe anaemia compared to the
highest SES group in Cohort 2 (95% CI = 1.5-10.8;
Table 3). In the RCT trial arms, maternal age and parity
were not associated with severe anaemia in bivariate
analysis (P-value ≥ 0.2). Trial arm was forced into the
final RCT model, even though it was not associated
with severe anaemia in bivariate analysis (HR = 1.09,
95% CI = 0.77-1.52) and remained non-significant fol-
lowing multivariable adjustment. The following factors
were associated with increased severe anaemia failure in
the RCT arms following multivariable adjustment: Kenyan
site (HR = 2.76, 95% CI = 1.79-4.25) using Burkina Faso
as reference, advanced HIV disease (HR = 2.11, 95%
CI = 1.19-3.75) and prolonged breastfeeding (> = 6 months)
(HR = 1.62, 95% CI = 1.00-2.62). The following factors
were associated with reduced risk following multivariable
adjustment: longer cumulative duration of ARV (HR =
0.05, P-value = 0.003), and marginally the South African
site (HR = 0.52, P-value = 0.054).
Log rank P-value (Hb 11.0g/dL)=0.026
Log rank P-value(Hb 8.0-10.9g/dL)=0.587
Enrolment Hb=8.0-10.9g/dL
RCT A: triple ARV
RCT B: ZDV plus sdNVP
Enrolment Hb 11.0g/dL
RCT A: triple ARV
RCT B: ZDV plus sdNVP
Figure 3 Kaplan-Meier failure curve showing anaemia failure (Hb < 8.0 g/dL) in RCT intervention arms, stratified by enrolment Hb level.
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Discussion
The evidence from this trial shows the safety and effi-
cacy of combination antiretroviral drugs during preg-
nancy, delivery and breastfeeding and supports the
revised 2010 WHO guidelines [29].
While previous evidence indicates that ZDV may be
cytotoxic, so is HIV infection. The potential negative
consequences of longer durations of ZDV exposure are
seemingly ameliorated by the marked impact of triple
ARV drugs on HIV disease [29], evidenced by the rise in
CD4 cell count in RCT arm A, to levels around 150 cells
higher than RCT arm B at six months postpartum. This
group also had higher haemoglobin levels postpartum
than RCT arm B and lower rates of failure in those with-
out pre-existing anaemia. However, we did observe a
higher proportion of macrocytosis in RCT arm A
Table 1 Baseline characteristics of HIV-1 infected women enrolled in the Kesho Bora study, by intervention
arm (N = 1070)
Characteristic n (%) Cohort 1: Cohort 2: RCT arm A: RCT arm B:






(n = 118) (n = 128) (n = 412) (n = 412)
Country
Burkina Faso 46 (39.0) 48 (38) 128 (31.1) 123 (29.9)
Kenya 72 (61.0) 80 (62) 141 (34.2) 148 (35.9)
South Africa — — 143 (34.7) 141 (34.2)
Age (years) median (IQR) 28 (26–31) 26 (23–29) 27 (24–31) 27 (23–31)
Highest level of education attained
Never attended school 19 (16.1) 16 (12.5) 60 (14.6) 63 (15.3)
Primary 57 (48.3) 61 (47.7) 136 (33.0) 147 (35.7)
Secondary or higher 42 (35.6) 51 (39.8) 216 (52.4) 202 (49.0)
WHO HIV clinical stage
1 28 (23.7) 100 (78.1) 279 (67.7) 296 (71.8)
2 41 (34.8) 23 (18.0) 109 (26.5) 93 (22.6)
3 25 (21.2) 5 (3.9) 24 (5.8) 23 (5.6)
4 24 (20.3) 0 (0) 0 (0) 0 (0)
Nutritional status (BMI kg/m2)
Mean (SD) 25 (3.8) 26 (4.1) 27 (4.3) 27 (4.3)
Underweight: BMI < 18.5 3 (2.5) 1 (0.8) 1 (0.2) 2 (0.5)
Socio-economic quintile
Most poor 30 (25.4) 32 (25.0) 66 (16.0) 81 (19.7)
Very poor 29 (24.6) 36 (28.1) 83 (20.1) 71 (17.2)
Poor 27 (22.9) 35 (27.3) 72 (17.5) 80 (19.4)
Less poor 25 (21.2) 16 (12.5) 96 (23.3) 79 (19.2)
Least poor 7 (5.9) 9 (7.0) 95 (23.1) 101 (24.5)
Parity
Nulliparous (first pregnancy) 9 (7.6) 28 (21.9) 74 (18.0) 74 (18.0)
1 34 (28.8) 44 (34.4) 131 (31.8) 145 (35.2)
2 38 (32.2) 24 (18.7) 105 (25.5) 98 (23.8)
3 or more 37 (31.4) 32 (25.0) 102 (24.8) 95 (23.1)
Planned mode of feeding
Breastfeeding 60 (50.9) 92 (71.9) 300 (72.8) 297 (72.1)
Replacement feeding 55 (46.6) 29 (22.6) 105 (25.5) 103 (25.0)
Unknown, undecided or other 3 (2.5) 7 (5.5) 7 (1.7) 12 (2.9)
ART = antiretroviral therapy; triple ARV = triple-combination antiretroviral prophylaxis; ZDV plus sdNVP = zidovudine plus single-dose nevirapine; IQR = interquartile
range; std dev = standard deviation.
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Table 2 Clinical and haematological findings of enrolled women, by intervention arm
Characteristic Cohort 1: Cohort 2: RCT arm A: RCT arm B: P-






(n visits = 1514) (n visits = 1371) (n visits = 4467) (n visits = 4381)
Median weeks of antiretroviral use (IQR) 112.8 5.9 22.1 6.7 NA
(85.1-117.7) (4.7-6.8) (10.6-32.4) (4.6-8.9)
Number of women who never initiated
breastfeeding (formula only), n (%)
46 (38.9) 31 (24.2) 104 (25.2) 104 (25.2) 0.899*
Median weeks of breastfeeding
if initiated (IQR)
19.1 17.9 20.9 19.6 0.898
(11.9-23.2) (12.1-24.7) (11.9-24.9) (11.3-25.0)
Breastfeeding duration if initiated, n (%)
<3 months 28 (43.8) 42 (46.1) 120 (41.2) 133 (44.8)
≥3 months 36 (56.2) 49 (53.9) 171 (58.8) 164 (55.2) 0.385
Median CD4 count [cells/mm3] (IQR)
At enrolment 134.5 (91–170) 621.5 (559–810) 335.5 (282–408) 338.5 (267–408) 0.428*
At delivery 184 (129–277) 742 (602.5-910) 462.5 (383–603) 415 (331–527) <0.001*
At 6 months postpartum 274 (207–364) 731 (616–870) 479 (369–597) 374 (292–471) <0.001*
At 12 months postpartum 304 (228–419) 683.5 (543–889) 401 (319.5-518) 378 (287–469) 0.509*
Median Hb [g/dL] (IQR)
At enrolment 9.9 (8.9-11.0) 10.9 (9.9-12.7) 10.2 (9.2-11.1) 10.2 (9.1-11.1) 0.440*
At delivery 10.0 (8.9-11.8) 11.3 (10.2-13.3) 10.6 (9.6-11.6) 10.6 (9.4-11.8) 0.948*
At 6 months postpartum 11.8 (11.1-13.0) 13.1 (11.8-14.3) 11.9 (11.1-12.8) 11.7 (10.9-12.6) 0.075*
At 12 months postpartum 11.9 (11.0-12.9) 12.5 (11.4-13.6) 11.5 (10.7-12.5) 11.3 (10.3-12.2) 0.078*
Median MCV [fL] (IQR)
At enrolment 86 (78–91) 85 (78–91) 87 (81–93) 88.5 (82–94) 0.866*
At delivery 91 (84–98) 88 (80–93) 91 (83–99) 93 (85–101) 0.325*
At 6 months postpartum 103 (96–110) 82 (77–90) 91 (83–100) 85 (79–90) <0.001*
At 12 months postpartum 102 (95–110) 82 (75–89) 83 (77–89) 84 (78–90) 0.118*
Proportion with macrocytosis (95% CI)
At enrolment 0.03 (0.01-0.08) 0.05 (0.02-0.10) 0.10 (0.07-0.13) 0.07 (0.05-0.10) 0.259**
At delivery 0.21 (0.14-0.30) 0.08 (0.04-0.15) 0.23 (0.18-0.27) 0.28 (0.24-0.33) 0.112*
At 6 months postpartum 0.63 (0.53-0.71) 0.01 (0.00-0.07) 0.26 (0.21-0.30) 0.03 (0.02-0.06) <0.001*
At 12 months postpartum 0.61 (0.51-0.70) 0.01 (0.00-0.07) 0.06 (0.03-0.10) 0.09 (0.06-0.14) 0.144*
Proportion with any anaemia
(Hb < 11 g/dL) (95% CI)
At enrolment 0.74 (0.65-0.82) 0.55 (0.46-0.64) 0.71 (0.66-0.75) 0.72 (0.68-0.76) 0.627*
At delivery 0.71 (0.61-0.79) 0.43 (0.33-0.52) 0.61 (0.56-0.66) 0.59 (0.54-0.64) 0.561*
At 6 months postpartum 0.25 (0.18-0.34) 0.12 (0.06-0.2) 0.23 (0.19-0.28) 0.26 (0.21-0.30) 0.398
At 12 months postpartum 0.21 (0.14-0.30) 0.16 (0.09-0.25) 0.32 (0.26-0.38) 0.39 (0.34-0.45) 0.228*
Proportion with severe anaemia
(Hb < 8 g/dL) (95% CI)
At enrolment 0.09 (0.05-0.16) 0.04 (0.01-0.09) 0.06 (0.04-0.09) 0.07 (0.04-0.09) 0.671
At delivery 0.15 (0.09-0.23) 0.06 (0.02-0.12) 0.06 (0.04-0.09) 0.10 (0.07-0.13) 0.144*
At 6 months postpartum 0.02 (0–0.06) 0.01 (0.00-0.06) 0.01 (0.00-0.03) 0.02 (0.01-0.04) 0.255
At 12 months postpartum 0.01 (0–0.04) 0.00 (0.00-0.04) 0.02 (0.00-0.08) 0.03 (0.01-0.09) 0.678
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compared to B at 6 months follow-up. Improvements in
Hb in Cohort 1, which approximated levels in Cohort 2
by 12 months postpartum, further demonstrates the
positive effects of triple-ARV regimens on maternal Hb,
which compensate for any haemosuppressive effects of
ZDV. Overall, the prevalence of anaemia (Hb < 11 g/dL)
in this multi-country study population ranged between
55-74%, and are similar to levels in other African set-
tings [3-6]. This is a very important condition, given its
links with maternal morbidity and mortality, especially
among HIV-positive women [40,41].
Association between ARV use during pregnancy and
severe anaemia
A pronounced increase in Hb was observed in all groups
following initiation of antiretroviral drugs, particularly
post-childbirth. This phenomenon has been documented
in other randomized trials in treatment-naïve patients
(pregnancy was not an exclusion criteria in a meta-
analysis of 6 RCTs) [42]. All treatment groups displayed
an increase in Hb to reach a plateau gain of +1.5-2 g/dL.
Following treatment cessation in Cohort 2 (enrolment
CD4 > 500) we observed a decline in Hb, while the gains
made were maintained long term in the RCT groups and
extended in Cohort 1. The Hb decline in Cohort 2 ap-
pears to be more of a decline of Hb with progression of
HIV disease, given that they started the trial with higher
CD4 and Hb levels compared to the other groups. The
impact of the maternal package at enrolment (iron and
folic acid supplementation, presumptive treatment for
malaria and anti-helminthics) may also have contributed
to the rise in Hb.
No differences were detected between the two RCT
intervention arms in occurrence of severe anaemia fol-
lowing multivariable adjustment and tests suggested
equivalency.
Berhane et al. found that increased duration of ARV
use among women (mixed cohort of non-pregnant and
pregnant women [43]) resolved pre-existing anaemia
after ARV use for at least 6 months and reduced the de-
velopment of anaemia after 12 or more months of treat-
ment [40]. This association of ARV with improvement
of the anaemia has also been reported elsewhere [44].
Our findings suggest that a significant reduction in se-
vere anaemia risk among pregnant women already exists
after one month use of ARV and suggests significant
Table 2 Clinical and haematological findings of enrolled women, by intervention arm (Continued)
Cumulative incidence of severe anaemia
(Hb < 8 g/dL) (95% CI)
At delivery 0.14 (0.09-0.22) 0.05 (0.03-0.11) 0.09 (0.06-0.12) 0.08 (0.06-0.11) 0.512*
At 6 months postpartum 0.30 (0.23-0.39) 0.10 (0.06-0.16) 0.16 (0.13-0.20) 0.17 (0.14-0.21) 0.436*
At 12 months postpartum 0.33 (0.26-0.41) 0.11 (0.06-0.17) 0.18 (0.14-0.21) 0.19 (0.16-0.23) 0.712*
At 18 months postpartum 0.34 (0.27-0.42) 0.11 (0.06-0.17) 0.18 (0.15-0.22) 0.21 (0.17-0.25) 0.356*
Overall incidence of severe anaemia per
person year (Hb < 8 g/dL) (95% CI)
0.21 0.06 0.12 0.14 0.317*
(0.16-0.27) (0.04-0.10) (0.10-0.15) (0.12-0.18)
Number of single failures only
(Hb < 8 g/dL), n (%)
28 (23.7) 11 (8.6) 49 (11.9) 65 (15.8) 0.129*
Number of individuals with repeat
failures (Hb < 8 g/dL), n (%)
11 (9.3) 2 (1.6) 14 (3.6) 14 (3.3) 0.708*
Summed ii number of repeat failures, n 24 4 35 32 —
CI = confidence interval; IQR inter-quartile range; SD = standard deviation; Hb = haemoglobin; ART = antiretroviral therapy; triple ARV = triple-antiretroviral
prophylaxis; ZDV plus sdNVP = zidovudine plus single-dose nevirapine; i: comparing RCT arms only: χ2 (or Fishers Exact) test for categorical variables, Student's t
test for comparison of two means or ANOVA for comparison of multiple means, Rank Sum test if data were highly skewed, and log-rank test for equality of
survivor functions; ii: individuals x number of failures; *P-value <0.05 based on comparison of all 4 groups; **p-value between 0.05 and 0.10 in comparison of all
4 groups.
Figure 4 Incidence of severe anaemia (including 95%
confidence intervals) by ARV duration for all study arms
(includes delivery related failures occurring at median
t = 1.15 months following treatment initiation) (P-value
comparing incidence in <1 versus
1–1.9 month duration = 0.004).
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Table 3 Factors associated with severe anaemia (Hb <8.0 g/dL) using Multivariable Cox models by cohort and RCT arm





Adjusted HR P-valueii Unadjusted HR Adjusted HR P-valueii Unadjusted HR Adjusted HR P-valueii
(95% CI) (95% CI) i (95% CI) (95% CI) i (95% CI) (95% CI) i
Observational cohort
Cohort 1: ART (CD4 < 200) 52/118 — — — — — — — — —
Cohort 2: ZDV plus sdNVP
(CD4 > 500)
15/128 — — — — — — — — —
Intervention armiii
RCT arm A: Triple ARV
(CD4 200–500)iv/v
97/412 — — — — — — 1 1 —
RCT arm B: ZDV plus sdNVP
(CD4 200–500)iv/v
84/412 — — — — — — 1.09 (0.77,1.52) 0.78 (0.54,1.11) 0.166
Country
Burkina Faso 70/345 1 1 — 1 — — 1 1 —
Kenya 157/441 1.66 (0.88,3.13) 1.56 (0.80,3.07) 0.192 1.11 (0.41,3.02) — — 2.70 (1.76,4.13) 2.76 (1.79,4.25) <0.001
South Africa 21/281 — — — — — — 0.42 (0.23,0.75) 0.52 (0.26,1.01) 0.054
Age (enrolment) 248/1070 0.95 (0.88,1.02) 0.96 (0.89,1.04) 0.312 0.95 (0.82,1.11) — — 1.00 (0.97,1.04) — —
BMI (enrolment) 248/1070 1.02 (0.93,1.11) — — 0.97 (0.87,1.09) — — 0.96 (0.92,1.01) 1.00 (0.95,1.05) 0.964
Secondary or higher education
versus none or primary level (enrolment)
90/511 — — — — 0.57 (0.40,0.81) 0.85 (0.56,1.26) 0.413
HIV stage 3 vi versus stage
1 or 2 (enrolment)
48/101 1.31 (0.71,2.44) — — Insufficient observations — — 2.11 (1.18,3.79) 2.11 (1.19,3.75) 0.011
Most poor SES category versus
poor or least poor (enrolment)
73/209 1.44 (0.73,2.85) — — 5.13 (1.83,14.41) 4.08 (1.54,10.75) 0.005 1.57 (1.06,2.32) 1.13 (0.75,1.70) 0.567
First pregnancy (enrolment) 37/185 0.90 (0.34,2.41) — — 1.35 (0.44,4.19) — — 0.88 (0.56,1.40) — —
Never breastfed 69/285 1.49 (0.80,2.78) — — 0.24 (0.03,1.86) — — 1.00 (0.66,1.50) — —
Prolonged breastfeeding
< 6 months 138/640 1 1 — 1 1 — 1 1 —
> = 6 months 31/103 0.79 (0.28,2.23) — — 0.77 (0.19,3.13) 1.12 (0.27,4.76) 0.873 1.46 (0.88,2.41) 1.62 (1.00,2.62) 0.051
0 duration (did not breast-feed) 69/285 1.43 (0.74,2.79) — — 0.23 (0.03,1.80) 0.33 (0.04,2.48) 0.280 1.06 (0.69,1.61) 1.05 (0.68,1.62) 0.831
Cumulative duration on ARV
(in years, continuous scale)
248/1070 0.03 (0.00,0.27) 0.04 (0.00,0.29) 0.002 0.02 (0.00,vii) — — 0.03 (0.00,0.24) 0.05 (0.01,0.37) 0.003
CI = confidence interval; BMI = body mass index; SES = socio-economic status.
i: Test of proportional hazards assumption not violated for cohort specific and RCT models.
ii: log rank test.
iii: ART = antiretroviral therapy; triple ARV = triple-combination antiretroviral prophylaxis; ZDV plus sdNVP = zidovudine plus single-dose nevirapine.
iv: difference test result comparing the two RCT trial arms i.e. null that difference = 0 (P-value = 0.636).
v: equivalence test results comparing the two RCT trial arms (P-value = 0.323; null hypothesis of dissimilarity rejected at pre-specified level of 5%, and equivalence assumed).
vi: no participant s in the RCT arms with stage 4 at enrolment.



















clinical implications. Longer cumulative duration of
ARV use was also an important predictor of reduced severe
anaemia risk in the RCT trial arms and in cohort 1, even
after multivariable adjustment. A long term residual protec-
tion following prophylaxis cessation was also evident as ob-
served by the maintenance of Hb levels post treatment in
the RCT arms. This study thus provides further empirical
evidence to reassure policy makers about the safety of lon-
ger durations of exposure to ZDV-containing triple prophy-
laxis compared to a shorter ZDV-only regimen, especially
concerning the suspected haematological effects of ZDV-
containing prophylaxis taken for longer periods or during
lactation. Moreover, overall evidence is also reassuring
about the effects of combined ARV drugs on pregnancy
outcomes other than anaemia [26,29].
Factors associated with development of severe anaemia
Among HIV-positive observational cohort women who
were free of severe anaemia at baseline, only SES cat-
egory was independently associated with severe anaemia
risk. Conversely several factors were associated with se-
vere anaemia in the RCT arms following multivariable
adjustment. These factors are consistent with those
identified in previous studies [9,40,45-47]. These in-
cluded local setting (country), more advanced HIV dis-
ease, prolonged breastfeeding and duration of ARV. The
observed reduced anaemia risk in South African and
converse elevated risk in Kenya compared to Burkina
Faso, is likely explained by the fact that little or no mal-
aria exists in the study sites in South Africa while
malaria-associated anaemia is common in the Kenyan
site [48]. Nutritional differences between study sites also
cannot be discounted.
We did not observe a significant difference in severe
anaemia incidence when comparing women who did not
breastfeed to those who did. Notably however, breast-
feeding more than 6 months was associated with an in-
creased risk of anaemia in the trial arms of the study
population. Current WHO guidelines promote exclusive
breastfeeding for the first 6 months for women on ARV.
These guidelines suggest the introduction of an appro-
priate complementary food thereafter, and continued
breastfeeding for 12 months. The finding of raised an-
aemia risk may have implications for future decisions
about recommended duration of breastfeeding in HIV-
positive women, and should be further researched [9].
Study limitations
These data were analysed from a completed trial that
was not specifically designed to assess this secondary
outcome. Higher levels of care received by participants
may also limit the generalisability of study findings.
Women had more visits to antenatal clinics than those
in the general population, and thus likely received more
iron and vitamin supplementation, and adherence coun-
selling. Further, the study population was predominately
urban and may not be representative of rural women. As
women with severe anaemia were excluded from study
participation, we were unable to assess the effects of
zidovudine in this small group. Most previous PMTCT
studies similarly exclude women with severe anaemia at
enrolment [21-24]. We also included unscheduled visits
and this may have influenced the results as sicker
women might have received additional Hb screening
measures.
Conclusions
This study demonstrates that similar severe anaemia risk
exists when comparing the short and longer ZDV-
containing regimens. This should reassure policy makers
who are increasingly recommending longer ARV regi-
mens for PMTCT in low- and middle-income countries.
Until 2010, based on concerns around drug safety,
among other considerations, many of these countries
used much shorter regimens. The longer the period that
ARV’s are taken in pregnancy or breastfeeding, the lower
the risk of HIV in the infant. ARV duration is the most
critical factor in determining whether children acquire
HIV. The study also confirms the importance of key
independent predictors of anaemia, showing the groups
that require closer monitoring. Finally, ARV use for as
little as one month may be beneficial to reduce severe
anaemia risk among pregnant (and postpartum) women
and may provide long term protection following cessa-
tion of prophylaxis.
Endnote
aPercentage of the volume of whole blood that is made
up of red blood cells, normally ~40% in women.
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